Alimera Sciences, which is a biopharmaceutical company that focuses on developing products that treat retina-related diseases, filed last Friday with the SEC to raise up to $80 million in an initial public offering. The Alpharetta, GA-based company, which was founded in 2003, plans to list on the NASDAQ under the symbol ALIM. Credit Suisse, Citi, Cowen & Company and Oppenheimer are the underwriters on the deal. No pricing terms were disclosed.
